In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ikano Therapeutics, Inc.

Latest From Ikano Therapeutics, Inc.

Biogen Leans On Pipeline As Tecfidera, Spinraza See Q4 Sales Dip

The company sees aducanumab adding a modest boost to sales if approved, but there are another four Phase III programs with some major read-outs coming.

BioPharmaceutical Commercial

Finance Watch: Biopharma VC Deals Hit New Record Of $27.4bn In 2020

Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.

Financing Innovation

Deal Watch: Sanofi Teams Up With Biond On Novel Checkpoint Inhibitor

Days after buying Kymab, Sanofi partners with Israel’s Biond on IO candidate targeting ILT2. Gilead again tackles functional cure of hepatitis B in alliance with Vir.

Deals Business Strategies

Mérieux and Shire funds back NeuroPhage in $12.4 million round for Alzheimer's

NeuroPhage Pharmaceuticals, a privately held company based in Cambridge, Massachusetts, has been quietly advancing novel approaches to the treatment of neurodegenerative diseases, and now has gained attention by landing $12.4 million in new venture funding. It will use the funds to begin preparations for a Phase I trial of its lead candidate to treat Alzheimer's disease, NPT001, which disaggregates existing beta amyloid plaques.

Neurology Israel
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Nasal
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Intranasal Therapeutics, Inc.
UsernamePublicRestriction

Register